Group 1 - Dongbao Biological (SZ 300239) announced on August 29 that its 12th meeting of the 9th board of directors was held on August 28, 2025, in Baotou, where the proposal to revise the "Information Disclosure Management System" was reviewed [1] - For the year 2024, Dongbao Biological's revenue composition is 100.0% from biological and biochemical products [1]

Core Viewpoint - Dongbao Bio (300239.SZ) reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 369 million yuan, a year-on-year decrease of 16.93% [1] - The net profit attributable to shareholders of the listed company was 36.97 million yuan, reflecting a year-on-year decrease of 28.00% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 33.44 million yuan, down 27.41% year-on-year [1] - Basic earnings per share were reported at 0.0629 yuan [1]

Core Viewpoint - Dongbao Biological (300239.SZ) reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved operating revenue of 369 million yuan, a year-on-year decrease of 16.93% [1] - The net profit attributable to shareholders was 36.97 million yuan, down 28.00% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 33.44 million yuan, reflecting a 27.41% decline compared to the previous year [1] - Basic earnings per share were reported at 0.0629 yuan [1]

包头东宝生物技术股份有限公司关于募集资金 2025 年半年度存放与使用情况的专项报告 2025 年 1 月 1 日至 2025 年 6 月 30 日 （本专项报告除特别注明外，均以人民币元列示） 证券代码：300239 证券简称：东宝生物 公告编号：2025-060 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 关于募集资金2025年半年度存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、 募集资金基本情况 （一） 向特定对象发行股票募集资金情况 1、 募集资金金额及到位时间 2021 年 5 月，经中国证券监督管理委员会证监许可[2020]3058 号文同意注册，并 经深圳证券交易所同意，本公司由主承销商招商证券股份有限公司采取向特定对象发行 的方式发行人民币普通股（A 股）7,272.89 万股，每股发行价格人民币 5.60 元，募集 资金总额为 407,281,700.00 元，扣除与发行有关的费用合计人民币 10,588,219.76 元 （不含税）后，募集资金净额为人民币 396,693,480. ...

2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 司的关联关系 | 上市公司核算的 会计科目 | 2025年期初占 用资金余额 | 2025年半年度占 用累计发生金额 | 2025年半年度 占用资金的利 | 2025年半年度 偿还累计发生 | 2025年半年度 期末占用资金 | 占用形成原因 | 是否披露 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | （不含利息） | 息(如有） | 金额 | 余额 | | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | | - | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | | - | | 其他关联方及附属企业 | | | | | | | | ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-057 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司 2025 年半年度报告全文及摘要已于 2025 年 8 月 29 日在中国证监会指定的创业板信息披露网站(巨潮资讯网，网址： www.cninfo.com.cn)上披露，请投资者注意查看。 特此公告。 包头东宝生物技术股份有限公司 包头东宝生物技术股份有限公司 关于 2025 年半年度报告披露提示性公告 董事会 2025 年 8 月 29 日 ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-056 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 第九届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、包头东宝生物技术股份有限公司(以下简称"公司")第九届董事会第十 二次会议通知于 2025 年 8 月 18 日以直接送达或电子邮件等方式通知了全体董事、 高级管理人员。 6、本次会议的召集、召开和表决程序符合法律、行政法规、部门规章、规 范性文件和公司《董事会议事规则》、《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 与会董事认真审阅了有关议案并进行了表决。经与会董事一致同意，形成决 议如下： 1、审议通过了《2025 年半年度报告全文及摘要》 经审议，董事会认为：公司 2025 年半年度报告全文及摘要真实、准确、完 整地反映了公司 2025 年半年度的实际经营情况，不存在任何虚假记载、误导性 陈述或重大遗漏，报告编制和审核程 ...

包头东宝生物技术股份有限公司 信息披露事务管理制度 (2025 年 8 月) 第一章 总则 第一条 为规范包头东宝生物技术股份有限公司（以下简称"公司"）信息 披露行为，促进公司依法规范运作，确保公司信息披露的真实、准确、完整与及 时，切实维护公司股东、债权人及其利益相关人的合法权益，依据《中华人民共 和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称 《证券法》）、《上市公司信息披露管理办法》、《上市公司治理准则》等规定 及《深圳证券交易所创业板股票上市规则》（以下简称《上市规则》）、《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《公 开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》、 《包头东宝生物技术股份有限公司章程》（以下简称《公司章程》）的有关规定， 制定本制度。 第二条 本制度所称"信息"是指可能对公司证券及其衍生品种交易价格 或者投资决策产生较大影响的信息或事项，以及中国证监会及其派出机构、深圳 证券交易所要求披露的信息；本制度所称"披露"是指在规定的时间内、在指定 的媒体上、以规定的方式向社会公众公布前述信息，并按规 ...

Financial Performance - The company's operating revenue for the reporting period was CNY 369,055,800.99, a decrease of 16.93% compared to CNY 444,275,439.67 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was CNY 36,967,330.23, down 28.00% from CNY 51,341,802.92 year-on-year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 33,435,102.10, a decrease of 27.41% compared to CNY 46,062,959.25 in the previous year[23]. - The net cash flow from operating activities was CNY 50,292,504.65, down 16.37% from CNY 60,138,978.92 in the same period last year[23]. - Basic earnings per share were CNY 0.0629, a decline of 27.28% from CNY 0.0865 in the previous year[23]. - Diluted earnings per share were CNY 0.0579, down 26.71% from CNY 0.0790 year-on-year[23]. - The weighted average return on net assets was 2.14%, a decrease of 0.91% compared to 3.05% in the previous year[23]. - Total assets at the end of the reporting period were CNY 2,576,371,394.20, a decrease of 1.85% from CNY 2,624,919,556.21 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company were CNY 1,705,824,856.12, down 1.94% from CNY 1,739,542,623.39 at the end of the previous year[23]. Dividend and Shareholder Returns - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has repurchased a total of 10,573,400 shares, accounting for 1.7812% of the current total share capital, as part of its commitment to shareholder returns[44]. Market and Industry Insights - The Chinese nutritional health food retail market exceeded USD 37 billion in 2023, with a compound annual growth rate of 7.0% over the past three years, expected to maintain a growth rate of 6.2% in the next three years[33]. - The pharmaceutical industry is projected to maintain an average annual growth rate of over 8% during the 14th Five-Year Plan period, indicating strong market potential[31]. - The company is positioned to benefit from increasing consumer awareness of health and wellness, with a growing demand for collagen in nutrition and beauty products[32]. - The market for gelatin capsules, primarily made from gelatin, is closely tied to the development of the pharmaceutical industry, presenting opportunities for growth[31]. Product Development and Innovation - The company focuses on the development of "natural collagen" and aims to become a comprehensive enterprise group in the health industry, covering medical, beauty, health, and food sectors[30]. - The company has launched plasma gelatin, which is expected to expand its application in the medical field, including hemostatic materials and drug delivery systems[34]. - The company is focusing on the collagen industry strategy, with a new product "Beyou Mianpai Collagen Protein Vitamin C Powder" receiving market approval and being launched[43]. - The company is actively expanding its product matrix into new application areas, with several R&D projects making substantial progress and resulting in multiple patents[43]. - The company has established a comprehensive product layout in the collagen industry, enhancing its competitive advantage through product innovation and quality improvement[30]. - The company has made significant progress in R&D, including a low-endotoxin gelatin project with endotoxin levels reduced to below 30 EU/g[46]. - The company has launched new products in the health food sector, including collagen peptide powders and solid beverages, expanding its product offerings[51]. Financial Management and Investments - The company reported a significant increase in financial expenses by 130.74%, primarily due to increased interest expenses and decreased interest income[60]. - The company has established stable partnerships with major pharmaceutical companies, enhancing its market position and brand influence[56]. - The company plans to expand its global market presence while continuing to leverage its brand advantages and technological innovations[58]. - The company has cumulatively used CNY 278,316,118.82 of the raised funds, with CNY 160,859,104.04 allocated for permanent working capital[80]. - The company raised a total of RMB 455 million through the issuance of 4,550,000 convertible bonds, with a net amount of RMB 442.26 million after deducting issuance costs[81]. Operational Efficiency and Management - The company is implementing measures to improve operational efficiency and management effectiveness, focusing on shareholder rights and steady share repurchase[43]. - The company is enhancing its supply chain resilience by optimizing procurement strategies and establishing a dynamic supplier management system[43]. - The company is focusing on digital transformation to improve management efficiency and cost control, enhancing market competitiveness[49]. - The company is committed to enhancing the quality and safety of its products in response to increasing consumer demands for high-quality health products[36]. Regulatory and Compliance - The company has established a comprehensive quality management system, successfully passing regulatory inspections and customer audits during the reporting period[49]. - The company has received multiple certifications, including BRCGS and ISO9001, indicating its commitment to quality management and safety standards[52]. - Regulatory risks are increasing in the healthcare and nutrition sectors, necessitating the company's active participation in industry standards and compliance management[104]. Strategic Partnerships and Collaborations - The company is deepening collaborations with leading enterprises in the industry, resulting in further growth in export business[44]. - The company is focusing on strategic partnerships with high-quality production enterprises to promote the "Yuan Su" series of new products, enhancing market responsiveness[87]. Employee Engagement and Corporate Governance - Employee welfare is prioritized, with initiatives for health checks and cultural activities to enhance workplace environment and employee engagement[118]. - The company emphasizes the protection of shareholder and creditor rights by enhancing corporate governance and internal control systems, ensuring high-quality information disclosure[116]. Future Outlook - The company plans to expand its market presence by launching two new products in Q3 2025, targeting a 10% increase in market share[200]. - The future outlook remains positive, with projected revenue growth of 10% for the next half-year, driven by new product launches and market expansion[200].

Core Insights - Dongbao Bio is showcasing its self-developed medical blood plasma gelatin product, which has been included in the national list of innovative consumer goods, promoting import substitution in the biomedicine and regenerative medicine sectors [2] - The establishment of a "Technology Empowerment Party Building Alliance" aims to explore new development paths through the integration of party building and business operations [4] Group 1 - The automated production line at Dongbao Bio is operating efficiently, demonstrating the company's commitment to technological innovation in the biopharmaceutical field [2] - The alliance has gathered several high-tech enterprises and research institutions, including Shanghai Jiao Tong University Baotou Materials Research Institute, to facilitate resource sharing and collaborative activities [4] - The local government has introduced eight measures to accelerate technological innovation, including special funding for project support, which has led to a patent signing amount exceeding 320 million yuan and a total of 7,279 effective patents [6]